The pan-cancer efficacy of repotrectinib was shown in the phase I/II registrational trial TRIDENT-1 (NCT03093116), which included patients with advanced solid tumors harboring ALK, ROS, or NTRK rearrangements. This evidence concerns the gene ALK and cancer.